BioSpace News Archive

- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by t

-The quantitative test kits detect the level of COVID-19 antibodies that correlate to virus neutralization -Kantaro test achieves 97.8% sensitivity and 99.6% specificity for the presence of COVID-19 antibodies -Because no proprietary equipment is required, the Kantaro kits are scalable across global testing laboratories

Sage Science to Distribute Universal Sequencing Technology’s TELL-Seq™ Linked-Read NGS Library Prep Kits Linked-read technology paired with SageHLS instrument enables targeted sequencing of large gene targets using short-read sequencers BEVERLY, Mass. & CANTON, Mass.--( BUSINESS WIRE )-- Sage Science, a developer of products for improving sample preparation processes in life science applications, and Universal Sequencing Technology today announ

The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™ . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005299/en/ The Abiomed Breethe OXY-1 System has received 510(k) clearance from the United St

NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, announces that it will release its third quarter 2020 financial and operating results for the period ended September 30, 2020 on Monday, November 9, 2020 prior to the start of trading. Management will host a conference call and webcast at 8:30am ET on that day. Conference call and webcast details Monday, November 9, 2020 @

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2020 financial results after the market closes on Monday November 9, 2020.

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that the U.S. Food and Drug Administration (FDA) granted TRC102 orphan drug

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Postmarketing Analysis of Misuse, Abuse and Diversion of Xtampza ER,” was published in the peer-reviewed medical journal, Pain Medicine.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that new data from the global Phase 2 clinical trial of mavrilimumab in giant cell arteritis (GCA) will be presented at the late-breaking abstracts session during the American College of Rheumatology (ACR) Convergence 2020.

PetMed Express, Inc. announced its financial results for the quarter ended September 30, 2020.